Adaptive Biotechnologies (ADPT) Tops Q1 EPS by 12c

Adaptive Biotechnologies (NASDAQ: ADPT) reported Q1 EPS of ($0.29), $0.12 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $38.4 million versus the consensus estimate of $27.75 million.

“We started the year strong with revenue increasing 84% year over year, driven by growth in both our sequencing and development revenue categories,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “I am encouraged by the solid momentum across all areas of our business as we continue to capitalize on the multiple opportunities originating from our platform.”

GUIDANCE:

Adaptive Biotechnologies sees FY2021 revenue of $145-155 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth